Skip to main content

LCD L34082: Varicose Veins of the Lower Extremity, Treatment of

LCD L34082, Varicose Veins of the Lower Extremity, Treatment of, is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2026-10-08 and first in force 2015-10-01. The policy text runs 1,146 words, and its billing and coding article A57305 lists 46 ICD-10-CM codes that support medical necessity for 26 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 46 covered ICD-10-CM codes: 1 more code than L33575 (Wellpoint Federal, 45 codes, revised 2026-04-01).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2026-10-08
Original effective
2015-10-01
Policy text
1,146 words
Covered ICD-10 codes (articles)
46

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L34082
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Billing and coding article A57305: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A57305 (Billing and Coding: Varicose Veins of the Lower Extremity, Treatment of) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A57305: Billing and Coding: Varicose Veins of the Lower Extremity, Treatment of (Billing and Coding, effective 2026-10-08)

Covered ICD-10-CM codes
46
1 group
Non-covered ICD-10-CM codes
24
Procedure codes listed
26
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A57305
ICD-10-CMDescription (FY2027)
I80.01Phlebitis and thrombophlebitis of superficial vessels of right lower extremity
I80.02Phlebitis and thrombophlebitis of superficial vessels of left lower extremity
I80.03Phlebitis and thrombophlebitis of superficial vessels of lower extremities, bilateral
I80.3Phlebitis and thrombophlebitis of lower extremities, unspecified
I83.001Varicose veins of unspecified lower extremity with ulcer of thigh
I83.002Varicose veins of unspecified lower extremity with ulcer of calf
I83.003Varicose veins of unspecified lower extremity with ulcer of ankle
I83.004Varicose veins of unspecified lower extremity with ulcer of heel and midfoot
I83.005Varicose veins of unspecified lower extremity with ulcer other part of foot
I83.011Varicose veins of right lower extremity with ulcer of thigh
I83.012Varicose veins of right lower extremity with ulcer of calf
I83.013Varicose veins of right lower extremity with ulcer of ankle
I83.014Varicose veins of right lower extremity with ulcer of heel and midfoot
I83.015Varicose veins of right lower extremity with ulcer other part of foot
I83.021Varicose veins of left lower extremity with ulcer of thigh
I83.022Varicose veins of left lower extremity with ulcer of calf
I83.023Varicose veins of left lower extremity with ulcer of ankle
I83.024Varicose veins of left lower extremity with ulcer of heel and midfoot
I83.025Varicose veins of left lower extremity with ulcer other part of foot
I83.11Varicose veins of right lower extremity with inflammation
I83.12Varicose veins of left lower extremity with inflammation
I83.211Varicose veins of right lower extremity with both ulcer of thigh and inflammation
I83.212Varicose veins of right lower extremity with both ulcer of calf and inflammation
I83.213Varicose veins of right lower extremity with both ulcer of ankle and inflammation

Procedure codes: 36465, 36466, 36468, 36470, 36471, 36473, 36474, 36475, 36476, 36478, 36479, 36482, 36483, 37700, 37718, 37722, 37735, 37760, 37761, 37765, 37766, 37780, 37799, 76942, 93970, 93971.

Coverage indications, limitations and medical necessity

Abstract:

Varicose veins are caused by venous insufficiency as a result of valve reflux (incompetence). The venous insufficiency results in dilated, tortuous, superficial vessels that protrude from the skin of the lower extremities. Spider veins (telangiectases) are dilated capillary veins that are most often treated for cosmetic purposes. Treatment of telangiectases CPT code 36468) is not covered by Medicare.

Ligation and stripping of varicose veins is a treatment option that aims to eliminate reflux at the saphenofemoral junction. The treatment of choice for moderate to large symptomatic varicose veins, ligation and stripping of the saphenous vein, has the lowest failure rate.

Sclerotherapy, injecting sclerosing solutions directly into the abnormal veins, is an alternative occasionally selected for the treatment of varicose veins without significant saphenofemoral or saphenopopliteal incompetence. However, it is not considered to be as reliable and effective as surgical ligation and stripping.

Sclerotherapy for cosmetic purposes is considered not medically necessary. Sclerotherapy is considered medically necessary for the treatment of small to medium sized vessels (less than or equal to 4 mm in diameter.) Sclerotherapy is not considered medically necessary for vessels larger than 4 mm in diameter.

Foam sclerotherapy of the saphenous vein at its junction with the deep venous system has been proposed as an alternative to ligation or saphenectomy, but its efficacy lacks significant scientific evidence to support its widespread use. The current consensus is that most recommendations for conventional sclerotherapy also apply to foam sclerotherapy.

Sclerotherapy of the saphenous vein at its junction with the deep system is not a covered procedure.

Non-compressive sclerotherapy involves injection of a sclerosant into a vein without the application of a compressive dressing. Because it is not effective in producing long-term obliteration of the incompetent veins, noncompressive sclerotherapy is not covered by Medicare.

Compressive sclerotherapy is the injection of the sclerosant into an empty vein (elevated limb) followed by application of a compressive bandage or dressing. This is the most commonly performed sclerotherapy procedure for varicose veins of the lower extremity. Compressive sclerotherapy is indicated for local small to medium symptomatic varices, isolated incompetent perforators, or recurrence of symptomatic varices after adequate surgical removal of varices. It is not considered an appropriate option for large, extensive or truncal varicosities.

High ligation and compression sclerotherapy refers to ligation of a truncal junction (saphenofemoral or saphenopopliteal) followed by compressive sclerotherapy of one or more veins.

Endovenous radiofrequency ablation (EFRA) and laser ablation are minimally invasive alternatives to vein ligation and stripping. Endovenous radiofrequency ablation is FDA-approved for treatment of the greater saphenous vein, perforators and tributary veins. Endovenous laser ablation is FDA-approved for the treatment of varicose veins and varicosities associated with superficial reflux of the greater saphenous vein.

Indications:

Medicare will consider interventional treatment of varicose veins (sclerotherapy, ligation with or without stripping, and endovenous radiofrequency or laser ablation) medically necessary if the patient remains symptomatic after a six-week trial of conservative therapy. The components of the conservative therapy include, but are not limited to:

• weight reduction,

• a daily exercise plan,

• periodic leg elevation, and

• the use of graduated compression stockings.

The conservative therapy must be documented in the medical record.

The patient is considered symptomatic if any of the following signs and symptoms of significantly diseased vessels of the lower extremities are documented in the medical record:

• stasis ulcer of the lower leg, as above,

• significant pain and significant edema that interferes with activities of daily living,

• bleeding associated with the diseased vessels of the lower extremities,

• recurrent episodes of superficial phlebitis,

• stasis dermatitis, or

• refractory dependent edema.

Additional indications and limitations are discussed according to type of treatment.

In addition to the requirement for failure of a six-week trial of conservative treatment and the symptoms described above, coverage of endovenous ablation therapy is limited to patients with:

• a maximum vein diameter of 20 mm for laser ablation;

• absence of thrombosis or vein tortuosity, which would impair catheter advancement; and

• absence of significant peripheral artery disease.

Radiofrequency/laser ablation is covered only for treatment of the lesser or greater saphenous veins to improve symptoms attributable to saphenofemoral or saphenopopliteal reflux. Coverage is only for FDA devices specifically approved for these procedures.

Non-cosmetic sclerotherapy will also be covered if performed in conjunction with surgical ligation or stripping procedures in appropriately selected patients.

Limitations:

Duplex ultrasound is often used in conjunction with other non-invasive physiologic testing to define the anatomy and physiology of the varicose vein network prior to injection or surgical intervention. There is adequate evidence that the pre-procedural ultrasound is helpful, and Medicare will cover a pre procedure Duplex scan CPT code 93970 or 93971) used in conjunction with other non-invasive physiologic testing CPT code to determine the extent and configuration of the varicosities. CGS expects that these studies will be performed by the provider planning to provide the therapy. CGS will allow this study once per provider or provider group. Clinical experience supports the use of ultrasound during the sclerotherapy procedure, and evidence shows that the outcomes may be improved and complication rates may be minimized when ultrasound guidance is used.

Medicare will cover intraoperative ultrasonic guidance in situations when it is medically necessary.

Medicare includes payment for the ultrasound in the payment for the ERFA and laser ablation procedures.

Cosmetic surgery is statutorily excluded from coverage by Medicare. The following interventional treatments are considered to be cosmetic and will be denied as such:

• Interventional treatment of asymptomatic varicosities.

• Treatment of telangiectases (36468).

• Sclerotherapy for cosmetic purposes.

Medicare cannot cover services which are not reasonable and necessary for the treatment of illness or injury or to improve the functioning of a malformed body member. The following interventional treatments are not considered medically reasonable or necessary and are denied as such:

• Interventional treatment of symptomatic varicosities without documentation of a failed six week trial of conservative therapy.

• Sclerotherapy for vessels larger than 4 mm in diameter.

• Reinjection following recanalization or failure of vein closure without recurrent signs or symptoms.

• Sclerotherapy of the saphenous vein at its junction with the deep system.

• Noncompressive sclerotherapy.

• Compressive sclerotherapy for large, extensive or truncal varicosities.

• Sclerotherapy, ligation and/or stripping of varicose veins, or endovenous ablation therapy are not covered for pregnant women, or patients with the inability to tolerate compressive bandages or stockings; severe distal arterial occlusive disease; obliteration of deep venous system; an allergy to the sclerosant; or a hypercoaguable state.

• Any interventional treatment that uses equipment or sclerosants not approved for such purposes by the FDA.

• Laser ablation of veins with a diameter greater than 20 mm.

• Endovenous ablation therapy in the presence of thrombosis or venous tortuosity which would impair catheter advancement.

CPT codes 37760 and 37761 should not be reported in conjunction with CPT codes 76937, 76942, 76998 or 93971.

Summary of evidence (opening)

N/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2026-10-08
Last reviewed by the contractor
2026-09-22
MCD version
31
Derived from
L31849

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

Prior authorization in Original Medicare

  • Hospital outpatient departments need prior authorization nationwide for dates of service on or after July 1, 2020; it is a condition of payment for the hospital claim and related claims. CMS service group: Vein ablation and related services. Codes on the CMS list: 36473, 36474, 36475, 36476, 36478, 36479, 36482 and 36483.
  • Ambulatory surgical centers in the CMS prior authorization demonstration: January 19, 2026 in California, Florida, Georgia, Maryland, New York, Pennsylvania and Tennessee; February 16, 2026 in Arizona, Ohio and Texas; requests are voluntary, and claims without one go to pre-payment review. CMS service group: Vein ablation and related services. Codes on the CMS list: 36473, 36475, 36478 and 36482; 36474, 36476, 36479 and 36483 were removed on January 1, 2026.

Medicare Advantage plans run their own prior authorization lists. See the services and codes on the Medicare prior authorization list.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L34082 cover?

Varicose veins are caused by venous insufficiency as a result of valve reflux (incompetence). The venous insufficiency results in dilated, tortuous, superficial vessels that protrude from the skin of the lower extremities. Spider veins (telangiectases) are dilated capillary veins that are most often treated for cosmetic purposes. Treatment of telangiectases CPT code 36468) is not covered by Medicare. The full 1,146-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L34082 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L34082?

The companion billing and coding article A57305 lists 46 ICD-10-CM codes in 1 group that support medical necessity and 24 that do not; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L34082?

A denial under LCD L34082 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A57305's 46 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.